Design Therapeutics, Inc. - Common Stock — Liquidità (NASDAQ:DSGN) | MetaTrader

Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Flusso di cassa derivante dalle attività operative -29.38 M-51.32 M-58.56 M-43.1 M-54.36 M -54 M Flussi di cassa derivanti dalle attività di investimento -53.64 M-220.99 M52.54 M43.95 M22.91 M 7.45 M Liquidità derivante dalle attività di finanziamento 379.21 M235 K724 K513 K25.74 M 45.65 M Liquidità libera -29.38 M-51.32 M-58.56 M-43.1 M-54.55 M -54.12 M

Notizie

FDA Extends Review Time for AZN's Camizestrant Combo in Breast Cancer

AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast Cancer

Design Therapeutics Stock Wobbles After Rare Genetic Disease Data - Design Therapeutics (NASDAQ:DSGN)

Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript

This Biotech Leader Ran Up As Much As 18% — And Then Lost It All

RBC Capital alza il target price su Design Therapeutics dopo i dati del trial

Design Therapeutics riporta dati della fase 1/2 per DT-216P2 nell’atassia di Friedreich

Il titolo di Design Therapeutics balza del 27% dopo dati positivi

Design Therapeutics annuncia dati positivi per il trattamento dell’atassia di Friedreich

Cramer: Design Therapeutics Is ‘Pure Spec,’ Buy This Health Care Stock - BillionToOne (NASDAQ:BLLN), Desi

Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know

Design Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:DSGN) 2026-04-30